<DOC>
	<DOCNO>NCT01247246</DOCNO>
	<brief_summary>This phase 2b , double-blind , placebo-controlled , 4-arm , adaptive-design trial , initially stratify cisplatin regimen , randomize 1:1:1:1 . The study conduct subject receive ChemoRT treatment squamous cell carcinoma ( SCCs ) oral cavity , oropharynx , hypopharynx , larynx . The study include treatment period approximately 7 week , depend subject 's prescribe radiation plan , Week 1 Week 4 post RT follow-up visit . It also include long follow-up period approximately 12 month determine effect SCV 07 tumor response ChemoRT .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Three Different Doses SCV 07 Attenuating Oral Mucositis Subjects With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Willing able understand sign inform consent form ( ICF ) study approve Investigator 's local central Institutional Review Board ( IRB ) Have recently diagnose , pathologically confirm , nonmetastatic SCC oral cavity , oropharynx , hypopharynx , larynx treat ChemoRT firstline treatment ; subject history surgical management eligible Have plan receive continuous course conventional external beam irradiation deliver intensitymodulated radiotherapy ( IMRT ) single daily fraction 2.0 2.2 Gy , cumulative radiation dose 50 72 Gy . Planned radiation treatment field must include least 2 oral site ( buccal mucosa , floor oral cavity , tongue , soft palate ) , site receive ≥ 50 Gy Have plan receive standard cisplatin CT regimen administer triweekly ( 80 100 mg/m2 , Days 0 , 21 , 42 ) weekly ( 30 40 mg/m2 ) Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Have adequate hematopoietic , hepatic , renal function screen visit : Hematopoietic function Hemoglobin ≥ 10 g/dL Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 Platelet count ≥ 100 × 109/L Hepatic function Total bilirubin &lt; 1.5 time uppernormal limit ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.0 time ULN Renal function : Serum creatinine concentration ≤ 2 mg/dL ; result ≥ 1.4 mg/dL ≤ 2.0 mg/dL , 24hour urinary creatinine clearance test must perform site 's local laboratory . To eligible study , subject must demonstrate 24hour urinary creatinine clearance ≥ 50 mL/min Have negative serum pregnancy test woman childbearing potential Agree use medically acceptable method birth control study participation 30 day follow last CTM treatment woman childbearing potential Males female age 18 year old . Tumor lip , sinus , salivary gland , nasopharynx , unknown primary tumor Metastatic disease ( M1 ) Stage IV C Prior radiation head neck Plan treat cetuximab ( Erbitux® ) Have undergone induction CT History malignant tumor , exclude nonmelanoma skin cancer curatively excise situ cervical carcinoma Have major surgical procedure , HNC , significant traumatic injury within 4 week prior initiation RT ; anticipation need major surgical procedure study Active infectious disease , exclude oral candidiasis Have OM baseline visit Have diagnosis autoimmune disease require chronic immunosuppression Known seropositivity HIV , HBV , HCV Prior use SCV 07 Have use investigational agent within 30 day randomization Are pregnant breastfeed Known allergy intolerance cisplatin Unable give inform consent comply study requirement , include complete subject diary QOL instrument Have condition therapy , opinion Investigator , would make subject unsuitable study unable comply followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Oral Mucositis</keyword>
	<keyword>Head Neck</keyword>
	<keyword>Head Neck Neoplasms</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Stomatitis</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Mouth Diseases</keyword>
	<keyword>Stomatognathic Diseases</keyword>
	<keyword>SCV-07</keyword>
</DOC>